Biodexa Pharmaceuticals Plc(BDRX)Earnings, Financials & Key Ratios
BDRX•NASDAQ
$4.86
$1M mkt cap·Price updated May 7, 2026
AboutBiodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of familial adenomatous polyposis, non-muscle invasive bladder cancer, and Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma. In addition, the company offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release therapeutics; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. It has collaboration agreements with Janssen and Melior. The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.Show more
- Revenue$0
- EBITDA-$8M+11.0%
- Net Income-$6M-9.0%
- EPS (Diluted)-60.00+100.0%
- ROE-63.37%+28.1%
- ROIC-120.34%+42.9%
- Debt/Equity0.01-93.9%
- Interest Coverage-120.77
BDRX Key Insights
Biodexa Pharmaceuticals Plc (BDRX) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Strong 5Y profit CAGR of 22.4%
- ✓Share count reduced 11.4% through buybacks
- ✓Trading at only 0.0x book value
✗Weaknesses
- ✗Weak momentum: RS Rating 2 (bottom 2%)
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
BDRX Price & Volume
Biodexa Pharmaceuticals Plc (BDRX) stock price & volume — 10-year historical chart
Loading chart...
BDRX Growth Metrics
Biodexa Pharmaceuticals Plc (BDRX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-100%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM17.9%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM49.52%
Return on Capital
10 Years-86.9%
5 Years-117.42%
3 Years-129.12%
Last Year-75.95%
BDRX Peer Comparison
Biodexa Pharmaceuticals Plc (BDRX) competitors in Drug Delivery Technology Platforms — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 SIGA | 338.88M | 4.73 | 14.33 | -31.8% | -43117.39% | -10.67% | 0.00 | |
 NUVB | 1.67B | 4.82 | -8.03 | 6.99% | -102.06% | -44.1% | 0.03 | |
 IMVT | 5.53B | 27.22 | -9.97 | -47.07% | 0.00 | |||
 PRAX | 9.63B | 333.28 | -24.72 | -100% | -43.02% | 0.00 | ||
 ACAD | 3.86B | 22.57 | 9.85 | 11.87% | 34.3% | 35.65% | 0.04 | |
 INVA | 1.93B | 22.80 | 6.91 | 18.52% | 118.91% | 46.47% | 0.23 | |
 AVXL | 289.14M | 3.12 | -5.78 | -31.55% | ||||
 CORT | 5.48B | 51.05 | 62.26 | 12.79% | 6.23% | 7.5% | 0.01 |
Compare BDRX vs Peers
Biodexa Pharmaceuticals Plc (BDRX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
BDRX Income Statement
Biodexa Pharmaceuticals Plc (BDRX) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 989K | 1.94M | 674K | 343K | 578K | 699K | 381K | 0 | 0 |
| Revenue Growth % | -25.25% | 95.96% | -65.22% | -49.11% | 68.51% | 20.93% | -45.49% | -100% | - |
| Cost of Goods Sold | 8.33M | 9.36M | 7.84M | 6.07M | 4.65M | 5.11M | 4.07M | 5.44M | 184.86K |
| COGS % of Revenue | 842.16% | 482.92% | 1163.65% | 1769.1% | 805.19% | 731.19% | 1067.45% | - | - |
| Gross Profit | -7.34M▲ 0% | -7.42M▼ 1.1% | -7.17M▲ 3.4% | -5.72M▲ 20.1% | -4.08M▲ 28.8% | -4.41M▼ 8.2% | -3.69M▲ 16.5% | -5.44M▼ 47.5% | -184.86K▲ 96.6% |
| Gross Margin % | -742.16% | -382.92% | -1063.65% | -1669.1% | -705.19% | -631.19% | -967.45% | - | - |
| Gross Profit Growth % | -14.56% | -1.1% | 3.4% | 20.14% | 28.8% | -8.24% | 16.46% | -47.5% | 96.6% |
| Operating Expenses | 5.54M | 4.39M | 3.67M | 17.32M | 2.92M | 4.52M | 4.33M | 3.76M | 8.08M |
| OpEx % of Revenue | 559.76% | 226.73% | 543.77% | 5048.11% | 505.54% | 646.64% | 1135.96% | - | - |
| Selling, General & Admin | 4.44M | 4.39M | 4.16M | 4.96M | 2.95M | 4.54M | 4.34M | 3.79M | 4.84M |
| SG&A % of Revenue | 448.53% | 226.73% | 617.8% | 1445.48% | 509.69% | 649.79% | 1139.63% | - | - |
| Research & Development | 9.83M | 9.36M | 7.84M | 16.15M | 4.65M | 5.11M | 4.07M | 5.44M | 3.73M |
| R&D % of Revenue | 993.83% | 482.92% | 1163.65% | 4707.29% | 805.19% | 731.19% | 1067.45% | - | - |
| Other Operating Expenses | 0 | 0 | -8.34M | -3.79M | -4.68M | -5.13M | -4.08M | -5.47M | -482.54K |
| Operating Income | -11.78M▲ 0% | -11.81M▼ 0.3% | -11.32M▲ 4.2% | -23.04M▼ 103.6% | -7M▲ 69.6% | -8.93M▼ 27.6% | -8.01M▲ 10.3% | -9.2M▼ 14.8% | -8.27M▲ 10.1% |
| Operating Margin % | -1190.7% | -609.65% | -1679.23% | -6717.2% | -1210.73% | -1277.83% | -2103.41% | - | - |
| Operating Income Growth % | -22.01% | -0.33% | 4.21% | -103.57% | 69.63% | -27.64% | 10.28% | -14.79% | 10.11% |
| EBITDA | -10.61M | -10.7M | -10.03M | -21.82M | -6.59M | -8.76M | -7.73M | -9.08M | -8.08M |
| EBITDA Margin % | -1072.7% | -552.32% | -1488.58% | -6362.39% | -1141% | -1252.93% | -2029.13% | - | - |
| EBITDA Growth % | -100.09% | -0.9% | 6.27% | -117.51% | 69.78% | -32.8% | 11.73% | -17.48% | 10.99% |
| D&A (Non-Cash Add-back) | 1.17M | 1.11M | 1.28M | 1.22M | 403K | 174K | 283K | 117K | 184.86K |
| EBIT | -12.86M | -11.81M | -10.83M | -23.44M | -6.06M | -8.44M | -7.44M | -9.2M | -8.27M |
| Net Interest Income | -94K | -585K | -89K | -33K | -44K | -24K | 42K | 2K | 18.58K |
| Interest Income | 15K | 2K | 8K | 1K | 0 | 29K | 83K | 2K | 87.05K |
| Interest Expense | 109K | 587K | 97K | 34K | 44K | 53K | 41K | 0 | 68.47K |
| Other Income/Expense | -1.19M | -585K | 395K | -430K | 892K | 444K | 529K | 3.22M | 1.92M |
| Pretax Income | -12.97M▲ 0% | -12.4M▲ 4.4% | -10.92M▲ 11.9% | -23.47M▼ 114.9% | -6.11M▲ 74.0% | -8.49M▼ 39.0% | -7.49M▲ 11.8% | -5.98M▲ 20.1% | -6.35M▼ 6.2% |
| Pretax Margin % | -1311.43% | -639.83% | -1620.62% | -6842.57% | -1056.4% | -1214.31% | -1964.57% | - | - |
| Income Tax | -1.26M | -2.03M | -1.78M | -1.28M | -646K | -832K | -406K | -250K | -102.7K |
| Effective Tax Rate % | 9.75% | 16.39% | 16.34% | 5.46% | 10.58% | 9.8% | 5.42% | 4.18% | 1.62% |
| Net Income | -11.71M▲ 0% | -10.37M▲ 11.4% | -10.09M▲ 2.7% | -22.19M▼ 120.0% | -5.46M▲ 75.4% | -7.66M▼ 40.2% | -7.08M▲ 7.5% | -5.73M▲ 19.1% | -6.24M▼ 9.0% |
| Net Margin % | -1183.52% | -534.98% | -1496.29% | -6469.1% | -944.64% | -1095.28% | -1858.01% | - | - |
| Net Income Growth % | -89.99% | 11.42% | 2.73% | -120.02% | 75.39% | -40.22% | 7.54% | 19.07% | -8.99% |
| Net Income (Continuing) | -11.71M | -10.37M | -9.14M | -22.19M | -5.46M | -7.66M | -7.08M | -5.73M | -6.24M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -999999.00▲ 0% | -999999.00▲ 0.0% | -999999.00▲ 0.0% | -999999.00▲ 0.0% | -999999.00▲ 0.0% | -999999.00▲ 0.0% | -229000.00▲ 77.1% | -999999.00▼ 336.7% | -60.00▲ 100.0% |
| EPS Growth % | 20.33% | 6.44% | 93.29% | 55.99% | 75.4% | -40.23% | 95.37% | -405.24% | 99.99% |
| EPS (Basic) | -999999.00 | -999999.00 | -999999.00 | -999999.00 | -999999.00 | -999999.00 | -229000.00 | -999999.00 | -60.00 |
| Diluted Shares Outstanding | 0 | 0 | 0 | 1 | 1 | 1 | 30 | 61.95K | 54.86K |
| Basic Shares Outstanding | 0 | 0 | 0 | 1 | 1 | 1 | 30 | 61.95K | 54.86K |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
BDRX Balance Sheet
Biodexa Pharmaceuticals Plc (BDRX) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 18.58M | 5.62M | 13.74M | 9.28M | 11.76M | 4.69M | 7.03M | 8.81M | 12.42M |
| Cash & Short-Term Investments | 13.2M | 2.34M | 10.93M | 7.55M | 10.06M | 2.84M | 5.97M | 1.67M | 8.52M |
| Cash Only | 13.2M | 2.34M | 10.93M | 7.55M | 10.06M | 2.84M | 5.97M | 1.67M | 8.52M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 2.23M | 89K | 1.81M | 95K | 33K | 329K | 704K | 715K | 221.61K |
| Days Sales Outstanding | 823.74 | 16.76 | 980.73 | 101.09 | 20.84 | 171.8 | 674.44 | - | - |
| Inventory | 941K | 0 | 0 | 0 | 0 | 0 | -704K | 0 | 0 |
| Days Inventory Outstanding | 41.24 | - | - | - | - | - | - | - | - |
| Other Current Assets | 1.58M | 3.05M | 847K | 1.38M | 1.06M | 1.15M | 704K | 0 | 0 |
| Total Non-Current Assets | 30.64M | 14.83M | 17.16M | 542K | 1.15M | 837K | 3.51M | 5.97M | 5.73M |
| Property, Plant & Equipment | 2.53M | 1.98M | 2.15M | 542K | 1.15M | 831K | 571K | 324K | 90.84K |
| Fixed Asset Turnover | 0.39x | 0.98x | 0.31x | 0.63x | 0.50x | 0.84x | 0.67x | - | - |
| Goodwill | 13.44M | 2.29M | 2.29M | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 14.2M | 10.08M | 10.09M | 0 | 0 | 6K | 2.94M | 5.65M | 5.64M |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 465K | 469K | 2.63M | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | 49.22M▲ 0% | 20.44M▼ 58.5% | 30.89M▲ 51.1% | 9.82M▼ 68.2% | 12.91M▲ 31.5% | 5.53M▼ 57.2% | 10.54M▲ 90.8% | 14.78M▲ 40.2% | 18.15M▲ 22.8% |
| Asset Turnover | 0.02x | 0.09x | 0.02x | 0.03x | 0.04x | 0.13x | 0.04x | - | - |
| Asset Growth % | -13.17% | -58.47% | 51.12% | -68.22% | 31.54% | -57.21% | 90.81% | 40.2% | 22.78% |
| Total Current Liabilities | 8.36M | 2.47M | 5.67M | 2.99M | 1.84M | 1.9M | 5.57M | 5.03M | 6.12M |
| Accounts Payable | 2.27M | 286K | 725K | 337K | 485K | 339K | 314K | 707K | 0 |
| Days Payables Outstanding | 99.52 | 11.15 | 33.74 | 20.27 | 38.04 | 24.21 | 28.18 | 47.46 | - |
| Short-Term Debt | 322K | 288K | 179K | 107K | 0 | 0 | 0 | 0 | 60.89K |
| Deferred Revenue (Current) | 0 | 0 | 0 | 68K | 0 | 197K | 0 | 1.47M | 570K |
| Other Current Liabilities | 2.64M | 792K | 2.77M | 1.62M | 664K | 386K | 4.23M | 921K | 5.49M |
| Current Ratio | 2.22x | 2.27x | 2.42x | 3.10x | 6.39x | 2.47x | 1.26x | 1.75x | 2.03x |
| Quick Ratio | 2.11x | 2.27x | 2.42x | 3.10x | 6.39x | 2.47x | 1.39x | 1.75x | 2.03x |
| Cash Conversion Cycle | 765.46 | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 6.18M | 1.05M | 5.67M | 110K | 619.53K | 463K | 295K | 1.42M | 643.87K |
| Long-Term Debt | 6.16M | 714K | 4.76M | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 29K | 170K | 912K | 60K | 620K | 463K | 295K | 118K | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 165K | 0 | 50K | -469 | 0 | 0 | 1.31M | 643.87K |
| Total Liabilities | 14.55M | 3.52M | 11.34M | 3.1M | 2.46M | 2.36M | 5.86M | 6.46M | 6.76M |
| Total Debt | 6.55M | 1.25M | 6.08M | 260K | 766K | 624K | 464K | 727K | 60.89K |
| Net Debt | -6.66M | -1.09M | -4.85M | -7.29M | -9.29M | -2.21M | -5.51M | -942K | -8.46M |
| Debt / Equity | 0.19x | 0.07x | 0.31x | 0.04x | 0.07x | 0.20x | 0.10x | 0.09x | 0.01x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Interest Coverage | -117.99x | -20.12x | -111.61x | -689.29x | -137.77x | -159.15x | -181.56x | - | -120.77x |
| Total Equity | 34.68M▲ 0% | 16.92M▼ 51.2% | 19.56M▲ 15.6% | 6.72M▼ 65.7% | 10.45M▲ 55.6% | 3.16M▼ 69.7% | 4.68M▲ 47.9% | 8.32M▲ 77.9% | 11.38M▲ 36.8% |
| Equity Growth % | -24.16% | -51.19% | 15.56% | -65.65% | 55.59% | -69.75% | 47.94% | 77.9% | 36.81% |
| Book Value per Share | - | - | - | 999999.00 | 999999.00 | 999999.00 | 155933.33 | 134.33 | 207.52 |
| Total Shareholders' Equity | 34.68M | 16.92M | 19.56M | 6.72M | 10.45M | 3.16M | 4.68M | 8.32M | 11.38M |
| Common Stock | 3K | 3K | 23K | 63K | 98.47K | 108.34K | 1.19M | 6.69M | 14.07M |
| Retained Earnings | -74.65M | -89.72M | -99.84M | -122.43M | -127.8M | -135.34M | -144.77M | -150.42M | -102.62M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 56.39M | 53.7M | 53.49M | 54.72M | 53M | 53M | 61.52M | 53M | 1.19M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
BDRX Cash Flow Statement
Biodexa Pharmaceuticals Plc (BDRX) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -12.95M | -13.45M | -6.49M | -9.3M | -6.01M | -7.05M | -6.83M | -12.26M | -5.39M |
| Operating CF Margin % | -1309.71% | -694.01% | -962.76% | -2711.66% | -1039.45% | -1008.3% | -1791.6% | - | - |
| Operating CF Growth % | 1.02% | -3.84% | 51.75% | -43.33% | 35.4% | -17.31% | 3.15% | -79.62% | 56.01% |
| Net Income | -16.06M | -15.03M | -10.09M | -22.19M | -5.46M | -7.66M | -7.08M | -5.73M | -6.24M |
| Depreciation & Amortization | 1.17M | 1.11M | 1.28M | 1.22M | 403K | 343K | 283K | 254K | 184.86K |
| Stock-Based Compensation | 0 | 0 | -34K | -404K | 89K | 123K | 28K | 283K | 0 |
| Deferred Taxes | 0 | 0 | -1.78M | 13.2M | 469K | -832K | -406K | -250K | 0 |
| Other Non-Cash Items | 3.11M | -1.07M | 2.33M | 430K | -892K | 454K | 397K | -3.08M | -1.01M |
| Working Capital Changes | -1.17M | 1.54M | 1.8M | -1.56M | -617K | 520K | -49K | -3.74M | 1.68M |
| Change in Receivables | -968K | 1.03M | 725K | 493K | -487K | 7K | 365K | -5.97M | 2.57M |
| Change in Inventory | -202K | 347K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -892.99K |
| Cash from Investing | -1.47M | 9.04M | -3.81M | 2.57M | -278K | -220K | -265K | -598K | -658.25K |
| Capital Expenditures | -707K | -244K | -319K | -209K | -320K | -62K | -26K | -9K | -675.86K |
| CapEx % of Revenue | 71.49% | 12.59% | 47.33% | 60.93% | 55.36% | 8.87% | 6.82% | - | - |
| Acquisitions | 0 | 0 | -947K | 0 | 0 | 0 | 0 | 0 | 17.61K |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | -763K | 9.29M | 8K | 144K | 42K | -158K | -239K | -589K | 0 |
| Cash from Financing | 10.28M | -6.47M | 18.73M | 3.08M | 8.8M | 47K | 10.23M | 8.56M | 12.77M |
| Debt Issued (Net) | 4.68M | -5.88M | 3.86M | -6.18M | -215K | -178K | -188K | 245K | -440.14K |
| Equity Issued (Net) | 5.73M | 0 | 14.11M | 9.74M | 9.04M | 243K | 10.43M | 8.31M | 13.45M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | -136K | -587K | 766K | -476K | -15K | -18K | -13K | 0 | -240.61K |
| Net Change in Cash | -4.4M▲ 0% | -10.86M▼ 146.6% | 8.59M▲ 179.0% | -3.38M▼ 139.4% | 2.51M▲ 174.2% | -7.22M▼ 387.6% | 3.13M▲ 143.4% | -4.3M▼ 237.2% | 6.97M▲ 262.0% |
| Free Cash Flow | -13.66M▲ 0% | -13.69M▼ 0.2% | -6.81M▲ 50.3% | -9.51M▼ 39.7% | -6.33M▲ 33.5% | -7.11M▼ 12.4% | -7.09M▲ 0.3% | -13.04M▼ 83.9% | -5.4M▲ 58.6% |
| FCF Margin % | -1381.19% | -706.6% | -1010.09% | -2772.59% | -1094.81% | -1017.17% | -1860.63% | - | - |
| FCF Growth % | 5.36% | -0.25% | 50.28% | -39.69% | 33.46% | -12.36% | 0.3% | -83.88% | 58.6% |
| FCF per Share | - | - | - | -999999.00 | -999999.00 | -999999.00 | -236300.00 | -210.40 | -98.36 |
| FCF Conversion (FCF/Net Income) | 1.11x | 1.30x | 0.64x | 0.42x | 1.10x | 0.92x | 0.96x | 2.14x | 0.86x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
BDRX Key Ratios
Biodexa Pharmaceuticals Plc (BDRX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -13.31% | -29.12% | -40.19% | -55.29% | -168.89% | -63.6% | -112.47% | -180.59% | -88.14% | -63.37% |
| Return on Invested Capital (ROIC) | -23% | -30.3% | -40.42% | -55.58% | -244.34% | -1768.75% | -634.53% | -9934.71% | -210.63% | -120.34% |
| Gross Margin | -484.28% | -742.16% | -382.92% | -1063.65% | -1669.1% | -705.19% | -631.19% | -967.45% | - | - |
| Net Margin | -465.68% | -1183.52% | -534.98% | -1496.29% | -6469.1% | -944.64% | -1095.28% | -1858.01% | - | - |
| Debt / Equity | 0.05x | 0.19x | 0.07x | 0.31x | 0.04x | 0.07x | 0.20x | 0.10x | 0.09x | 0.01x |
| Interest Coverage | - | -117.99x | -20.12x | -111.61x | -689.29x | -137.77x | -159.15x | -181.56x | - | -120.77x |
| FCF Conversion | 2.12x | 1.11x | 1.30x | 0.64x | 0.42x | 1.10x | 0.92x | 0.96x | 2.14x | 0.86x |
| Revenue Growth | -3.78% | -25.25% | 95.96% | -65.22% | -49.11% | 68.51% | 20.93% | -45.49% | -100% | - |
BDRX Frequently Asked Questions
Biodexa Pharmaceuticals Plc (BDRX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Biodexa Pharmaceuticals Plc (BDRX) grew revenue by 0.0% over the past year. Growth has been modest.
Biodexa Pharmaceuticals Plc (BDRX) reported a net loss of $12.1M for fiscal year 2025.
Dividend & Returns
Biodexa Pharmaceuticals Plc (BDRX) has a return on equity (ROE) of -63.4%. Negative ROE indicates the company is unprofitable.
Biodexa Pharmaceuticals Plc (BDRX) had negative free cash flow of $18.7M in fiscal year 2025, likely due to heavy capital investments.
Explore More BDRX
Biodexa Pharmaceuticals Plc (BDRX) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates